Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation

Abstract

A rapid and fully automated chemiluminescent immunoassay for the detection of thyrotropin receptor autoantibodies (TSHR-Ab) based on a bridge technology was compared with two bioassays that measure either stimulating (TSAb) or blocking (TBAb) antibodies for the detection and differentiation of TSHR-Ab. A total of 229 patients with various thyroid disorders [151 with Graves’ disease (GD), 35 with Hashimoto’s thyroiditis (HT), 32 with nodular goiter, and 11 with thyroid cancer] were included. The bridge immunoassay was performed according to the manufacturer’s instructions (cut-off>0.55 IU/l). TSAb and TBAb were measured with reporter bioassays. Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (cut-off>34% inhibition). TSAb was reported as percentage of specimen-to-reference ratio (> 140 SRR%). The 3 TSHR-Ab assays were negative in all patients with benign euthyroid nodular goiter and differentiated thyroid cancer. In contrast, in all patients with GD, irrespective of the disease duration, TSHR-Ab positivity was present in 127 of 151 (84%) and 140 (93%) for the bridge assay and TSAb bioassay, respectively (p<0.001). Fifteen of 151 (10%) GD samples were positive in the TSAb bioassay but negative in the bridge assay. The bridge assay and the TSAb bioassay correlated positively (r=0.39, p<0.0001) in patients with GD. Both assays detected TSHR-Ab in all ten untreated hyperthyroid patients with GD. In GD patients with a duration of less than six months, 27/29 (93%) and 28 (97%) were TSHR-Ab positive with the bridge and TSAb bioassay, respectively. In comparison, TSHR-Ab were present in two of 35 (6%) and five (14%) HT patients with the bridge and TSAb bio-assay, respectively. TSHR blocking antibodies were present in one (3%) patient with HT and in two (1%) patients with GD; these two GD patients were also bridge assay positive but TSAb bioassay negative. In conclusion, the bridge immunoassay and both bioassays are highly sensitive for the detection of TSHR-Ab. The bridge assay is, however, also positive in the presence of TSHR blocking antibodies detected in a TBAb bioassay.

Key words

TSH receptor functional antibodies - bridge immunoassay - cell-based bioassay

^* SA and TD share first authorship.

^§ MS and GJK share senior authorship.

• References

• 1 Bartalena L. Diagnosis and management of Graves disease: A global overview. Nat Rev Endocrinol 2013; 9: 724-734
• 2 Furmaniak J, Sanders J, Nunez Miguel R. et al. Mechanisms of action of TSHR autoantibodies. Horm Metab Res 2015; 47: 735-752
• 3 Morshed SA, Davies TF. Graves’ Disease Mechanisms: The role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res 2015; 47: 727-734
• 4 Costagliola S, Morgenthaler NG, Hoermann R. et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J Clin Endocrinol Metab 1999; 84: 90-97
• 5 Shewring G, Smith BR. An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol (Oxf) 1982; 17: 409-417
• 6 Schott M, Hermsen D, Broecker-Preuss M. et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): An international multicentre trial. Clin Endocrinol (Oxf) 2009; 71: 566-573
• 7 Araki N, Iida M, Amino N. et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin. Eur Thyroid J 2015; 4: 14-19
• 8 Diana T, Kanitz M, Lehmann M. et al. Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid 2015; 25: 169-175
• 9 Giuliani C, Cerrone D, Harii N. et al. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab 2012; 97: E1080-E1087
• 10 Lytton SD, Ponto KA, Kanitz M. et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123-2131
• 11 Diana T, Daiber A, Oelze M. et al. Stimulatory TSH-Receptor antibodies and oxidative stress in graves disease. J Clin Endocrinol Metab 2018; 103: 3668-3677
• 12 Frank CU, Braeth S, Dietrich JW. et al. Bridge technology with TSH receptor chimera for sensitive direct detection of TSH receptor antibodies causing Graves’ disease: Analytical and clinical evaluation. Horm Metab Res 2015; 47: 880-888
• 13 Rapoport B, Chazenbalk GD, Jaume JC. et al. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673-716
• 14 Tahara K, Ban T, Minegishi T. et al. Immunoglobulins from Graves’ disease patients interact with different sites on TSH receptor/LH-CG receptor chimeras than either TSH or immunoglobulins from idiopathic myxedema patients. Biochem Biophys Res Commun 1991; 179: 70-77
• 15 Tahara K, Ishikawa N, Yamamoto K. et al. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor. Thyroid 1997; 7: 867-877
• 16 Li Y, Kim J, Diana T. et al. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol 2013; 173: 390-397
• 17 Kampmann E, Diana T, Kanitz M et al. Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: A prospective study. Int J Endocrinol 2015; 678194
• 18 Diana T, Li Y, Olivo PD. et al. Analytical performance and validation of a bioassay for thyroid-blocking antibodies. Thyroid 2016; 26: 734-740
• 19 Bossowski A, Moniuszko M, Idzkowska E. et al. Decreased proportions of CD4+IL17+/CD4+CD25+CD127- and CD4+IL17+/CD4+CD25+CD127 – FoxP3+T cells in children with autoimmune thyroid diseases. Autoimmunity 2016; 49: 320-328
• 20 Diana T, Wuster C, Kanitz M. et al. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016; 39: 1159-1165
• 21 Diana T, Wuster C, Olivo PD. et al. Performance and specificity of 6 immunoassays for tsh receptor antibodies: A multicenter study. Eur Thyroid J 2017; 6: 243-249
• 22 Diana T, Krause J, Olivo PD. et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 2017; 189: 304-309
• 23 Diana T, Olivo PD, Kahaly GJ. Thyrotropin receptor blocking antibodies. Horm Metab Res 2018; 50: 853-862
• 24 Leschik JJ, Diana T, Olivo PD. et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 2013; 139: 192-200
• 25 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26: 1343-1421
• 26 Kahaly GJ, Bartalena L, Hegedüs L. et al. European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 2018; 167-186
• 27 Allelein S, Ehlers M, Goretzki S. et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies. Horm Metab Res 2016; 48: 795-801
• 28 Tozzoli R, D’Aurizio F, Villalta D. et al. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease. Clin Chem Lab Med 2017; 55: 58-64
• 29 Diana T, Brown RS, Bossowski A. et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves’ disease-a multicenter study. J Clin Endocrinol Metab 2014; 99: 1648-1655
• 30 Kemble DJ, Jackson T, Morrison M. et al. Analytical and clinical validation of two commercially available immunoassays used in the detection of TSHR antibodies. J Appl Lab Med 2017; 2: 345-355
• 31 Diana T, Kahaly GJ. Thyroid stimulating hormone receptor antibodies in thyroid eye disease-methodology and clinical applications. Ophthalmic Plast Reconstr Surg 2018; 34: S13-S19
• 32 Lytton SD, Li Y, Olivo PD. et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 2010; 162: 438-446
• 33 Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. Auto Immun Highlights 2013; 4: 11-26